Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022

This is how her discovery got to cancer clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 1996, Carolyn Bertozzi and her lab at UC Berkeley were working to develop a way to image cell-surface glycans: sugar-based macromolecules that coat the surface of cells. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.​
Jacquelyn Cobb
Associate Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login